KPD Consolidation After ASCT in NDMM Patients

NCT06879379 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma, Newly Diagnosed

Interventions

DRUG: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation

Sponsor

Peking University People's Hospital